Theravance Biopharma Q3 2024 Earnings Report

Theravance Biopharma EPS Results

• Actual EPS: -$0.26
• Consensus EPS: -$0.10
• Beat/Miss: Missed by -$0.16
• One Year Ago EPS: -$0.17

Theravance Biopharma Revenue Results

• Actual Revenue: $16.87 million
• Expected Revenue: $16.11 million
• Beat/Miss: Beat by +$760.00 thousand
• YoY Revenue Growth: N/A

Theravance Biopharma Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes

Theravance Biopharma (NASDAQ:TBPH) is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.